Slovakia - Kislovakia - Adama

adama - od - polyalkylén oxid modifikovaného heptametyltrisiloxánu 204 g/l, + blok kopolymérov etylén oxidu a propylén oxidu 832 g/l, - adjuvanty, regulátory rastu a biostimulanty

Umoja wa Ulaya - Kislovakia - EMA (European Medicines Agency)

samsung bioepis nl b.v. - ranibizumab - wet macular degeneration; macular edema; diabetic retinopathy; myopia, degenerative - oftalmologiká - byooviz is indicated in adults for:the treatment of neovascular (wet) age-related macular degeneration (amd)the treatment of visual impairment due to diabetic macular oedema (dme)the treatment of proliferative diabetic retinopathy (pdr)the treatment of visual impairment due to macular oedema secondary to retinal vein occlusion (branch rvo or central rvo)the treatment of visual impairment due to choroidal neovascularisation (cnv).

Umoja wa Ulaya - Kislovakia - EMA (European Medicines Agency)

stada arzneimittel ag - ranibizumab - wet macular degeneration; macular edema; diabetic retinopathy; diabetes complications - oftalmologiká - ximluci is indicated in adults for:the treatment of neovascular (wet) age-related macular degeneration (amd)the treatment of visual impairment due to diabetic macular oedema (dme)the treatment of proliferative diabetic retinopathy (pdr)the treatment of visual impairment due to macular oedema secondary to retinal vein occlusion (branch rvo or central rvo)the treatment of visual impairment due to choroidal neovascularisation (cnv).

Umoja wa Ulaya - Kislovakia - EMA (European Medicines Agency)

roche registration gmbh - faricimab - wet macular degeneration; macular edema; diabetes complications - oftalmologiká - vabysmo is indicated for the treatment of adult patients with:neovascular (wet) age-related macular degeneration (namd),visual impairment due to diabetic macular oedema (dme).

Umoja wa Ulaya - Kislovakia - EMA (European Medicines Agency)

bayer ag - aflibercept - wet macular degeneration; macular edema; diabetes complications - oftalmologiká - eylea je indikovaný u dospelých na liečbu:neovascular (mokré) vekom podmienená makulárna degenerácia (amd);zraku v dôsledku makulárnej edém stredoškolské do žily sietnice occlusion (pobočka rvo alebo strednej rvo);zraku v dôsledku diabetickej makulárnej edém (dme);zraku v dôsledku krátkozrakého choroidal neovascularisation (krátkozrakého cnv).

Slovakia - Kislovakia - Ecolab

ecolab deutschland gmbh -

Slovakia - Kislovakia - Ecolab

ecolab deutschland gmbh -

Umoja wa Ulaya - Kislovakia - EMA (European Medicines Agency)

pharmaswiss ceska republika s.r.o - pegaptanibu - wet macular degeneration - oftalmologiká - macugen je indikovaný na liečbu neovaskulárnej (mokrej) vekom podmienenej makulárnej degenerácie (amd).

Slovakia - Kislovakia - ŠÚKL (Štátny ústav pre kontrolu liečiv)

covidien iic 15 hampshire street ma 02048 mansfield, ma spojené štáty americké -

Slovakia - Kislovakia - Ústav štátnej kontroly veterinárnych biopreparátov a liečiv

vétoquinol biowet, poľsko - tbl.